Does pulsatile administration of glucagon-like peptide-1 (GLP-1) when compared to continuous infusion have a greater effect on insulin secretion and blood glucose lowering in healthy humans?

Phase 1

Completed

• Conditions: Blood Glucose; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12612001040853
• Lead Sponsor: Royal Adelaide Hospital Intensive Care Unit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-09-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Healthy volunteers able to give informed consent

Exclusion Criteria

Inability to give informed consent
History of diabetes
Women who are pregnant or lactating
History of pancreatitis
Haemoglobin <125g/L for women and <135g/L for men
Glycated haemoglobin (HbA1c) >6.0 %
Ferritin levels for women <10microgram/L and <20microgram/L for men
Estimated glomerular filtration rate < 60ml/min
Impaired liver function (ALT: >55 U/L; Albumin: <34g/l; ALP: >110 U/L; Bilirubin: >25 micro mol; GGT: >80U/L)
Blood donation within the previous 12 weeks
BMI <18.5 or >30kgm^2
Taking blood-glucose lowering drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified